Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 1/20 | 0.54 |
| ▸ | HTR6 | P50406 | 10/20 | 0.54 |
| ▸ | PDE4A | P27815 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25423168 | 0.83 | SRC (0.41) | MTNR1BHTR6SRC | |
| SCHEMBL25748059 | 0.83 | HTR6 (0.60) | MTNR1BHTR6PDE4APDE4BPDE4C | |
| SCHEMBL25424320 | 0.80 | HTR6 (0.39) | MTNR1BHTR6PDE4APDE4BPDE4C | |
| SCHEMBL30405736 | 0.80 | HTR6 (0.39) | MTNR1BHTR6PDE4APDE4BPDE4C | |
| SCHEMBL25422879 | 0.79 | MTNR1B (0.55) | MTNR1BHTR6PDE4APDE4BPDE4C | |
| SCHEMBL25421448 | 0.76 | CA12 (0.51) | HTR6SRC | |
| SCHEMBL31579010 | 0.75 | PTGDR (0.39) | HTR6SRCACLY | |
| SCHEMBL22434661 | 0.74 | MAPT (0.40) | HTR6SRC | |
| SCHEMBL31027410 | 0.73 | HTR6 (0.46) | MTNR1BHTR6PDE4APDE4BPDE4C | |
| SCHEMBL31579098 | 0.73 | KDM4E (0.38) | HTR6SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4444300-A2 | INHIBITORS OF MENIN-MLL INTERACTION | Bala Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-118647378-A | Inhibitors of Mei Nen protein interaction with MLL | 巴拉疗法公司 | 2024-09-13 | — | — | CN | disclosed |
| WO-2023107696-A2 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, BMI1 | MTNR1B 558/4885HTR6 4128/4885PDE4A 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.